← All stocks

AGIOS PHARMACEUTICALS, INC.

AGIO Net buying
CIK 0001439222 #2036 in the set updated 17 Sep 2026
Bought (120 mo)
$101.96M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$116.82M
$5.94M on a plan · $79.87M straight out of an exercise
Sold at will
$31.02M
117 of 411 sales
Net
−$14.86M
+$70.94M against sales at will

By person

33 insiders · 430 transactions
6.6×

Brian Goff holds 6.6 times base salary in stock. $5.62M of shares against $846.86K in salary for 2025.

Salary from the company's own proxy. The shares are what Brian Goff last reported holding, valued at $30.48, the price Common stock was last bought or sold at on the open market here, on 4 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
CELGENE CORP /DE/ entity
10% owner
$69.53M (2)
+$69.53M
2,486,157
4.16%
$75.78M
+101.8%
Schenkein David P
Director
$249.98K (1)
$43.84M (63) scheduled
−$43.59M
397,014
0.6650%
$12.10M
+45.8%
Celgene European Investment Co LLC entity
10% owner
$30.92M (1)
+$30.92M
5,867,279
9.83%
$178.83M
+11.9%
NELSEN ROBERT
Director
$20.75M (15)
−$20.75M
109,230
0.1830%
$3.33M
−79.3%
Bowden Christopher
Chief Medical Officer
$12.62M (37) scheduled
−$12.62M
15,487
0.0259%
$472.04K
+1,086%
Biller Scott
Chief Scientific Officer
$12.34M (64) scheduled
−$12.34M
86,788
0.1454%
$2.65M
+16.4%
Goff Brian
Chief Executive Officer
$5.41M (19) scheduled
−$5.41M
184,508
0.3090%
$5.62M
Hoerter Steven L.
Chief Commercial Officer
$3.75M (10) scheduled
−$3.75M
10,941
0.0183%
$333.48K
Gheuens Sarah
Chief Medical Officer
$2.85M (24) scheduled
−$2.85M
54,645
0.0915%
$1.67M
+691.4%
Cantley Lewis Clayton Jr.
Director
$2.59M (66)
−$2.59M
158,990
0.2663%
$4.85M
−22.1%
Foster-Cheek Kaye I
Director
$2.24M (8) scheduled
−$2.24M
10,284
0.0172%
$313.46K
Burns James William
Chief Legal Officer
$2.10M (19) scheduled
−$2.10M
49,306
0.0826%
$1.50M
+406.2%
MARAGANORE JOHN
Director
$2.00M (3)
−$2.00M
30,028
0.0503%
$915.25K
−53.0%
Ballal Rahul D.
Director
$1.12M (5) scheduled
−$1.12M
15,230
0.0255%
$464.21K
Washburn Theodore James Jr.
Principal Accounting Officer
$1.06M (24)
−$1.06M
868
0.0015%
$26.46K
−71.1%
Jones Cecilia
Chief Financial Officer
$895.71K (15) scheduled
−$895.71K
54,998
0.0921%
$1.68M
+2,216%
Alenson Carman
Principal Accounting Officer
$773.19K (12)
−$773.19K
0
0.0000%
$0.00
−100.0%
Milanova Tsveta
Chief Commercial Officer
$741.86K (11) scheduled
−$741.86K
46,829
0.0784%
$1.43M
Miles Darrin
Chief Commercial Officer
$321.70K (3)
−$321.70K
7,209
0.0121%
$219.73K
+16.5%
Viswanadhan Krishnan
Chief Strategy and Operations
$184.97K (2) scheduled
−$184.97K
10,282
0.0172%
$313.40K
FOUSE JACQUALYN A
Director
$1.25M (1)
$1.14M (5) scheduled
+$112.27K
154,156
0.2582%
$4.70M
Scadden David
Director
$16.69K (1)
$98.22K (6) scheduled
−$81.54K
20,419
0.0342%
$622.37K
+5,404%
Hirsch Andrew
Chief Financial Officer
24,272
0.0407%
$739.81K
+808,967%
Biller Jonathan
Chief Financial Officer
22,953
0.0384%
$699.61K
+2,665%
Ho Maykin
Director
19,848
0.0332%
$604.97K
Car Bruce
Chief Scientific Officer
16,752
0.0281%
$510.60K
Smith Cynthia
Director
15,230
0.0255%
$464.21K
Owen Adams Catherine
Director
10,865
0.0182%
$331.17K
CAPELLO JEFFREY D
Director
10,865
0.0182%
$331.17K
Poddar Richa
Chief Commercial Officer
8,508
0.0143%
$259.32K
+1,112%
Clancy Paul J
Director
6,549
0.0110%
$199.61K
CLARK IAN T
Director
6,549
0.0110%
$199.61K
Backstrom Jay T.
Director
1,447
0.0024%
$44.10K
Insider
Date
Role
Action
Shares
Price
Amount
Bowden Christopher
5 Feb 2020
Chief Medical Officer
Exercised, kept
35,447
$35.16
$1.25M
Biller Scott
11 Jun 2019
Chief Scientific Officer
Exercised, kept
7,218
$2.34
$16.87K
Biller Scott
21 Dec 2018
Chief Scientific Officer
Exercised, kept
20,500
$2.34
$47.92K
Schenkein David P
10 Sep 2018
Chief Executive Officer
Exercised, kept
8,730
$31.64
$276.22K
Schenkein David P
5 Sep 2018
Chief Executive Officer
Exercised, kept
2,500
$31.64
$79.10K
Schenkein David P
5 Sep 2018
Chief Executive Officer
Exercised, kept
72,619
$2.34
$169.93K
Showing 250 of 430 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 487
Amendments (4/A) skipped 10
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 47
Sales straight out of an exercise 247
Sales at will 117
Transactions with no price 0
Shares from compensation/vesting 2,814,895
Sales filed before the plan box existed 106
History held since 31 Aug 2016